Axel R. Zander
- Hematology top 0.1%
- Hematopoietic Stem Cell Transplantation 106
- Acute Myeloid Leukemia Research 38
- Chronic Myeloid Leukemia Treatments 35
- Multiple Myeloma Research and Treatments 34
- Genetics top 0.2%
- Mesenchymal stem cell research 23
- Myeloproliferative Neoplasms: Diagnosis and Treatment 20
- Transplantation top 2%
- Immunology top 2%
- T-cell and B-cell Immunology 19
- Oncology top 1%
-
- Acute Lymphoblastic Leukemia research 25
- Co-authors
- Nicolaus KrögerBoris FehseTatjana ZabelinaClaudia LangeFrancis AyukHelmut RengesKarel A. DickeFlorian Tögel
- Cited by
- HematologyGeneticsTransplantation
- Partner nations
- GermanyUnited StatesRussia
In The Last Decade
Axel R. Zander
219 papers receiving 7.1k citations
Peers
Comparison fields: 5 of 127
- Hematology 3.8k
- Genetics 2.2k
- Transplantation 207
- Immunology 1.4k
- Oncology 1.7k
Countries citing papers authored by Axel R. Zander
This map shows the geographic impact of Axel R. Zander's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Axel R. Zander with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Axel R. Zander more than expected).
Fields of papers citing papers by Axel R. Zander
This network shows the impact of papers produced by Axel R. Zander. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Axel R. Zander. The network helps show where Axel R. Zander may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Axel R. Zander, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 2 | |
| 2 | 2017 | 2 | |
| 3 | 2017 | 3 | |
| 4 | Synergistic cytotoxic activity of treosulfan and gemcitabine in pancreatic cancer cell lines. | 2014 | 2 |
| 5 | 2010 | 21 | |
| 6 | A. J. Friedenstein, founder of the mesenchymal stem cell concept | 2009 | 30 |
| 7 | Initial report on a phase I clinical trial: Prevention and treatment of post-operative Acute Kidney Injury with allogeneic Mesenchymal Stem Cells in patients who require on-pump cardiac surgery | 2008 | 28 |
| 8 | Platelet lysate for rapid expansion of human mesenchymal stromal cells | 2008 | 1 |
| 9 | 2004 | 67 | |
| 10 | 2003 | 16 | |
| 11 | 2003 | 44 | |
| 12 | 2002 | 28 | |
| 13 | 2002 | 21 | |
| 14 | 2001 | 71 | |
| 15 | 2001 | 5 | |
| 16 | 2001 | 13 | |
| 17 | 2001 | 12 | |
| 18 | 2001 | 15 | |
| 19 | 1999 | 8 | |
| 20 | Die Transplantation hämatopoetischer Stammzellen : Teil II: Indikationen zur Transplantation von hämatopoetischen Stammzellen nach myeloablativer Therapie (Übersicht) | 1997 | 3 |
About Axel R. Zander
Axel R. Zander is a scholar working on Hematology, Genetics and Immunology, having authored 228 papers that have together received 7.3k indexed citations. Recurring topics across this work include Hematopoietic Stem Cell Transplantation (106 papers), Acute Myeloid Leukemia Research (38 papers), Chronic Myeloid Leukemia Treatments (35 papers), Multiple Myeloma Research and Treatments (34 papers), Acute Lymphoblastic Leukemia research (25 papers), Mesenchymal stem cell research (23 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (20 papers) and T-cell and B-cell Immunology (19 papers). The work is most often cited by research in Hematology (3.8k citations), Genetics (2.2k citations) and Transplantation (207 citations). Axel R. Zander has collaborated with scholars based in Germany, United States and Russia. Frequent co-authors include Nicolaus Kröger, Boris Fehse, Tatjana Zabelina, Claudia Lange, Francis Ayuk, Helmut Renges, Karel A. Dicke, Florian Tögel, Ulrike Bacher and William Krüger.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.